User login
Key clinical point: Once-monthly galcanezumab appeared to be effective and well-tolerated for up to 6 months in patients with episodic migraine.
Major finding: Patients who continued to receive galcanezumab showed sustained improvements in the least squares mean reduction in monthly migraine headache days from 4.01 at 3 months to 4.62 at 6 months, with the proportion of patients achieving ≥ 50% response increasing from 59.7% at 3 months to 70.9% at 6 months. No serious treatment-related adverse events were reported.
Study details: Findings are from a 3-month open-label extension (OLE) of the phase 3 PERSIST trial including 484 patients with episodic migraine who were previously assigned to receive galcanezumab (n = 243) or placebo (n = 241).
Disclosures: The PERSIST study was funded by Eli Lilly and Company. Three authors declared being full-time employees of Eli Lilly and Company while some other authors declared ties with various sources, including Eli Lilly.
Source: Zhou J et al. Galcanezumab in patients with episodic migraine: Results from the open-label period of the phase 3 PERSIST study. J Headache Pain. 2023;24:103 (Aug 4). doi: 10.1186/s10194-023-01613-1
Key clinical point: Once-monthly galcanezumab appeared to be effective and well-tolerated for up to 6 months in patients with episodic migraine.
Major finding: Patients who continued to receive galcanezumab showed sustained improvements in the least squares mean reduction in monthly migraine headache days from 4.01 at 3 months to 4.62 at 6 months, with the proportion of patients achieving ≥ 50% response increasing from 59.7% at 3 months to 70.9% at 6 months. No serious treatment-related adverse events were reported.
Study details: Findings are from a 3-month open-label extension (OLE) of the phase 3 PERSIST trial including 484 patients with episodic migraine who were previously assigned to receive galcanezumab (n = 243) or placebo (n = 241).
Disclosures: The PERSIST study was funded by Eli Lilly and Company. Three authors declared being full-time employees of Eli Lilly and Company while some other authors declared ties with various sources, including Eli Lilly.
Source: Zhou J et al. Galcanezumab in patients with episodic migraine: Results from the open-label period of the phase 3 PERSIST study. J Headache Pain. 2023;24:103 (Aug 4). doi: 10.1186/s10194-023-01613-1
Key clinical point: Once-monthly galcanezumab appeared to be effective and well-tolerated for up to 6 months in patients with episodic migraine.
Major finding: Patients who continued to receive galcanezumab showed sustained improvements in the least squares mean reduction in monthly migraine headache days from 4.01 at 3 months to 4.62 at 6 months, with the proportion of patients achieving ≥ 50% response increasing from 59.7% at 3 months to 70.9% at 6 months. No serious treatment-related adverse events were reported.
Study details: Findings are from a 3-month open-label extension (OLE) of the phase 3 PERSIST trial including 484 patients with episodic migraine who were previously assigned to receive galcanezumab (n = 243) or placebo (n = 241).
Disclosures: The PERSIST study was funded by Eli Lilly and Company. Three authors declared being full-time employees of Eli Lilly and Company while some other authors declared ties with various sources, including Eli Lilly.
Source: Zhou J et al. Galcanezumab in patients with episodic migraine: Results from the open-label period of the phase 3 PERSIST study. J Headache Pain. 2023;24:103 (Aug 4). doi: 10.1186/s10194-023-01613-1